RAS Mutations in Cancer Explained
Quick Facts
What are RAS mutations and why do they matter in cancer?
The RAS family includes three main genes, KRAS, NRAS and HRAS. Their proteins sit on the inner surface of the cell membrane and cycle between an inactive state bound to GDP and an active state bound to GTP. When active, they relay signals from growth-factor receptors to downstream pathways such as MAPK (RAF-MEK-ERK) and PI3K that tell a cell to grow and divide. Cancer-causing mutations impair the protein's ability to switch itself off, so growth signals keep firing.
RAS mutations are among the most frequent oncogenic alterations in human tumors. KRAS is the most commonly mutated of the three. It is altered in the large majority of pancreatic ductal adenocarcinomas (commonly cited as around 90%), in a substantial share of colorectal cancers, and in roughly a quarter to a third of lung adenocarcinomas. Exact rates vary by population, smoking history and the specific mutation, such as G12C, G12D or G12V. Because these tumors are common and often hard to treat, RAS has long been a major target for cancer researchers.
Why was KRAS considered undruggable for so long?
RAS proteins were identified as human oncogenes in the early 1980s, but turning that discovery into a medicine proved extremely difficult. The protein's affinity for GTP is so strong that competing molecules could not displace it, and the high concentration of GTP inside cells made direct competition unrealistic. The protein surface also lacked obvious deep pockets for conventional drugs. Efforts to block the enzymes that attach RAS to the membrane, or to inhibit downstream kinases, produced limited benefit and notable toxicity.
The breakthrough came with the KRAS G12C mutation, which introduces a cysteine that can be bound covalently by a drug when the protein is in its inactive state. The FDA granted accelerated approval to sotorasib in 2021 for KRAS G12C-mutated non-small cell lung cancer, and adagrasib followed in 2022. These approvals showed that KRAS could be drugged, although responses are often not durable because tumors develop resistance through new mutations or by reactivating signaling through other routes. G12C also accounts for only a fraction of KRAS-mutated cancers, leaving many patients without a matched option.
What are pan-RAS inhibitors and what challenges do they face?
Pan-RAS and broader RAS-targeting drugs are designed to act on many mutant forms, not just G12C, and some can engage RAS in its active state. This approach could extend targeted therapy to pancreatic and colorectal cancers driven by mutations such as G12D and G12V, and may slow resistance by shutting down more routes of RAS signaling. Several companies, including Revolution Medicines and Erasca, have candidates in clinical development, and researchers are watching closely to compare potency and tolerability.
The central trade-off is that normal cells also rely on RAS signaling. Inhibiting it broadly can cause side effects, such as skin rash and gastrointestinal symptoms, that may limit dosing. The key questions for upcoming trial data are whether a drug achieves meaningful tumor shrinkage, how long responses last, and whether patients can stay on treatment at an effective dose. Early-phase findings should be interpreted with caution, because small trial populations and short follow-up cannot confirm survival benefit. Larger randomized trials will be needed to establish where these drugs fit alongside chemotherapy and immunotherapy.
Frequently Asked Questions
RAS is a family of genes (KRAS, NRAS and HRAS) whose proteins control cell growth signaling. KRAS is the family member most often mutated in human cancers, particularly pancreatic, colorectal and lung cancers.
Yes. Tumor tissue or blood-based genomic testing can identify KRAS mutations and the specific variant, such as G12C. Guidelines generally recommend biomarker testing for advanced lung and colorectal cancers because results can affect treatment choice.
Approved KRAS-targeted drugs so far are specific to the G12C mutation. Broader pan-RAS inhibitors remain under clinical investigation, so patients interested in them should ask their oncologist about clinical trials.
References
- U.S. Food and Drug Administration. FDA grants accelerated approval to sotorasib for KRAS G12C-mutated NSCLC. May 2021.
- U.S. Food and Drug Administration. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. December 2022.
- STAT News. In cancer drug development, the spotlight shifts onto Erasca's KRAS-targeted treatment. November 2026.
- National Cancer Institute. The RAS Initiative: background on RAS-driven cancers.